Next 10 |
home / stock / nvsef / nvsef news
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...
2024-06-18 13:48:58 ET Summary Telix Pharmaceuticals' product revenues in full-year 2023 were $502.5 million, which was an increase of 214% from 2022 with revenues of only $160.1 million. TLX591 + best SOC is being used to treat patients with metastatic castration-resistant prosta...
2024-06-11 13:19:13 ET Summary Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size ...
2024-06-08 10:19:36 ET More on AstraZeneca, Bristol-Myers, etc. Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript) Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly ...
2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...
2024-06-06 07:09:15 ET More on Novartis, Roche, etc. Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Roche Is Joining The Obesity Party But Questions Remain SA Asks: Which weight-lo...
2024-06-03 17:24:06 ET Novartis AG (NVS) Investor Event at ASCO Conference Call June 02, 2024 07:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer Jeff Legos - Global...
2024-05-28 13:35:36 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript Travere Therapeutics Q1 2024 Earnings Preview Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant...
2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...